252 related articles for article (PubMed ID: 24697814)
1. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract][Full Text] [Related]
2. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
3. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
4. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
6. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
7. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
[TBL] [Abstract][Full Text] [Related]
8. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
10. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
11. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
13. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
Gusella M; Pasini F; Corso B; Bertolaso L; De Rosa G; Falci C; Modena Y; Barile C; Da Corte Z D; Fraccon A; Toso S; Cretella E; Brunello A; Modonesi C; Segati R; Oliani C; Minicuci N; Padrini R;
Pharmacol Res Perspect; 2020 Oct; 8(5):e00646. PubMed ID: 32813313
[TBL] [Abstract][Full Text] [Related]
14. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
[TBL] [Abstract][Full Text] [Related]
17. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
18. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
